Congratulations to Xenocor, Inc. for its Series A-2 Financing with its lead investor, GenHenn Capital Venture Fund I. Xenocor growth and mission is to provide groundbreaking development in laparoscopic technology. It will use the capital for the 2023 launch of Saberscope, the world’s first true HD, fog-free, articulating, single-use laparoscope. The transaction was closed on April 13, 2023.

“Xenocor is laser focused on facilitating the evolution of the 35-year-old laparoscopic visualization model to something that clearly better serves care givers and patients during minimally invasive surgery,” shared Charles DeCoster IV, CEO of Xenocor. “Our FDA cleared Saberscope improves visualization, dramatically diminishes workflow complexity, increases safety and reduces waste.”

The team was led by shareholder Russell K. Smith (Corporate, Salt Lake) and included associate William T. Morris (Corporate, Salt Lake City).